

Policies Repository



Policy Title Aztreonam (Cayston®)

Policy Number FS.CLIN.100

Application of Pharmacy Policy is determined by benefits and contracts. Benefits may vary based on product line, group or contract. Some medications may be subject to precertification, age, gender or quantity edits. Individual member benefits must be verified.

This Pharmacy Policy document describes the status of pharmaceutical information and/or technology at the time the document was developed. Since that time, new information relating to drug efficacy, interactions, contraindications, dosage, administration routes, safety or FDA approval may have changed. If the Medical/Pharmacy Reviewer is aware of any new information on the subject of this document, please provide it promptly to the Medical/Pharmacy Policy Department. This information may include new FDA approved indications, withdrawals or other FDA alerts. This type of information is relevant not only when considering whether this Policy should be updated, but also when applying it to current requests for coverage.

Members are advised to use participating pharmacies in order to receive the highest level of benefits.

Policy **Aztreonam (Cayston®)** is indicated to improve respiratory symptoms in cystic fibrosis patients with *Pseudomonas aeruginosa*.

The use of Aztreonam (Cayston®) requires prior authorization (ie, clinical pharmacy and/or Medical Director review).

Policy Description **Aztreonam (Cayston)** is a monobactam antibiotic that binds to penicillin binding proteins of susceptible bacteria which leads to inhibition of bacterial cell wall synthesis and death of the cell.

Policy Guideline Inclusion **Aztreonam (Cayston)** is approved in patients 7 years of age or older when all of the following inclusion criteria are met:

- Documentation of a diagnosis of Cystic fibrosis
- Documentation of Pseudomonas Aeruginosa in the lungs
- Documentation of FEV1 that is 25% to 75% of predicted

Policy Guideline Exclusion

Aztreonam (Cayston) is denied when any of the following exclusion criteria are present:

- Age less than 7 years
- No documentation of a diagnosis of Cystic fibrosis
- No documentation of Pseudomonas Aeruginosa in the lungs
- No documentation of FEV1 that is 25% to 75% of predicted

Policy List of Applicable Drugs

| Brand Name | Generic Name |
|------------|--------------|
| Cayston | Aztreonam |

Dosing and Administration

Refer to the specific manufacturer's prescribing information for administration and dosage details for each specific agent.

Policy References

Cayston [package insert]. Foster City CA. Gilead Sciences. 2010

Cayston website. Available at www.cayston.com. Accessed April 9, 2010.

Facts and Comparisons Website [Cayston]. Available at www.factsandcomparisons.com. Accessed April 9, 2010.

Gilead's Cayston Picks up panel endorsement but not based on data. Available at www.thepinksheet.com. Accessed April 9, 2010.

Gilead Prices Cystic Fibrosis Drug Cayston at slight premium to competitor. Available at www.thepinksheet.com. Accessed April 9, 2010.

McCoy K, Quittner A, Oermann C, et al. Inhaled Aztreonam Lysine for chronic airway pseudomonas

aeruginosa in cystic fibrosis. Am J Respir Crit Care Med. 2008; 178; 921-928.

Micromedex website [Cayston]. Available at www.micromedex.com. Accessed April 9, 2010.

NDA approval letter. Available at www.fda.gov. Accessed August 12, 2010.

Oermann C, Retsch-Bogart G, Quittner A, et al. An 18 month study of the safety and efficacy of repeated courses of inhaled Aztreonam Lysine in Cystic Fibrosis. Pediatric Pulmonology, 2010. 1-13.

Retsch-Bogart G, Quittner A, Gibson R, et al. Efficacy and Safety of inhaled Aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135; 1223-1232.

Policy Link to Related Policies

Printed

11/15/2010 08:59:59

The Policy Bulletins on this web site were developed to assist Independence Blue Cross and its subsidiaries ("IBC") in administering the provisions of the respective benefit programs, and do not constitute a contract. If you are an IBC member, please refer to your specific benefit program for the terms, conditions, limitations and exclusions of your coverage. IBC does not provide health care services, medical advice or treatment, or guarantee the outcome or results of any medical services/treatments. The facility and professional providers are responsible for providing medical advice and treatment. Facility and professional providers are independent contractors and are not employees or agents of IBC. If you have a specific medical condition, please consult with your doctor. IBC reserves the right at any time to change or update its Policy Bulletins. © 2008 Independence Blue Cross. All Rights Reserved. Current Procedural Terminology © 2008 American Medical Association. All Rights Reserved.